https://scholars.lib.ntu.edu.tw/handle/123456789/495045
標題: | Diarrhea associated with afatinib: An oral ErbB family blocker | 作者: | CHIH-HSIN YANG Reguart N Barinoff J Köhler J Uttenreuther-Fischer M Stammberger U O'Brien D Wolf J Cohen E.E. |
關鍵字: | afatinib; afatinib-associated adverse event; diarrhea; EGF receptor; gastrointestinal adverse event | 公開日期: | 2013 | 卷: | 13 | 期: | 6 | 起(迄)頁: | 729-736 | 來源出版物: | Expert Review of Anticancer Therapy | 摘要: | Gastrointestinal (GI) adverse events (AEs) are frequently observed in patients receiving EGF receptor (EGFR; also known as HER1 or ErbB1) tyrosine kinase inhibitor therapy. GI AEs are among the most common and most impactful on a patient's quality of life. Severe diarrhea can result in fluid and electrolyte losses, leading to dehydration, electrolyte imbalances and renal insufficiency. Afatinib is an irreversible, oral, ErbB family blocker, inhibiting EGFR (ErbB1), HER2 (ErbB2) and ErbB4 receptor kinases. It also inhibits transphosphorylation of ErbB3. Similar to reversible tyrosine kinase inhibitors of EGFR, GI AEs-in particular, diarrhea-have frequently been observed in afatinib-treated patients. This article summarizes current data on afatinib-associated diarrhea and provides strategies for its management. Patient education, early identification, timely management and ongoing assessment will help to prevent aggravation, afatinib dose reductions or therapy discontinuation, encouraging patient compliance and allowing patients to obtain the maximum therapeutic benefit from this agent. ? 2013 2013 Expert Reviews Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84879347777&doi=10.1586%2fera.13.31&partnerID=40&md5=6674220d622ab08bbf6e58b402351739 https://scholars.lib.ntu.edu.tw/handle/123456789/495045 |
ISSN: | 1473-7140 | DOI: | 10.1586/era.13.31 | SDG/關鍵字: | afatinib; antibiotic agent; antineoplastic agent; dacomitinib; epidermal growth factor receptor; epidermal growth factor receptor 2; epidermal growth factor receptor 4; erlotinib; gefitinib; lapatinib; loperamide; neratinib; non prescription drug; placebo; breast cancer; cancer combination chemotherapy; cancer patient; constipation; diarrhea; diet therapy; disease severity; drug dose escalation; drug dose reduction; drug efficacy; drug mechanism; drug megadose; drug safety; drug use; drug withdrawal; human; lung non small cell cancer; monotherapy; nausea; nutritional deficiency; patient education; practice guideline; protein phosphorylation; quality of life; recommended drug dose; review; stomatitis; treatment response; vomiting; Administration, Oral; Diarrhea; Humans; Protein Kinase Inhibitors; Quinazolines; Receptor, Epidermal Growth Factor; Receptor, erbB-2 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。